Life-threatening complications of systemic sclerosis

Critical Care Clinics

Volumn 18, Issue 4, 2002, Pages 819-839

  Cossio, Moises ^a   Menon, Yamini ^a   Wilson, Wendell ^a   DeBoisblanc, Bennett P ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ATROPINE; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOPHOSPHAMIDE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; ILOPROST; IMMUNOSUPPRESSIVE AGENT; INOTROPIC AGENT; METHOTREXATE; MIDAZOLAM; MYCOPHENOLIC ACID; NICARDIPINE; NITRIC OXIDE; NORADRENALIN; PREDNISONE; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN E1; PROTON PUMP INHIBITOR; SILDENAFIL; THYMOCYTE ANTIBODY; UNINDEXED DRUG; UNIPROST; VASODILATOR AGENT; WARFARIN;

ASPIRATION PNEUMONIA; BLOOD VESSEL REACTIVITY; CLINICAL TRIAL; DRUG MEGADOSE; DYSPNEA; ENTEROPATHY; GASTROINTESTINAL DISEASE; GONADAL DISEASE; HEADACHE; HEART CATHETERIZATION; HEART FAILURE; HEMORRHAGIC CYSTITIS; HUMAN; HYPOTENSION; INTENSIVE CARE; KIDNEY DISEASE; LUNG DISEASE; LUNG HEMORRHAGE; NAUSEA AND VOMITING; PARESTHESIA; PERICARDIAL DISEASE; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESTLESSNESS; REVIEW; SYSTEMIC SCLEROSIS; TECHNIQUE; THORAX PAIN; VERTIGO;

CATHETERIZATION, SWAN-GANZ; CLINICAL PROTOCOLS; HUMANS; HYPERTENSION, PULMONARY; INTENSIVE CARE; SCLERODERMA, SYSTEMIC; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 0036839352     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0704(02)00023-4     Document Type: Review

References (75)

1. Bar J, Ehrenfeld M, Rozenman J, et al. Pulmonary-renal syndrome in systemic sclerosis. Semin Arthritis Rheum 2001;30:403-10.
2. Minai OA, Dweik RA, Arroliga AC. Manifestations of scleroderma pulmonary disease. Clin Chest Med 1998;19:713-31.
3. Salerni R, Rodnan GP, Leon DF, et al. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 1977;86:394-9.
4. Steen VD, Medsger Jr. TA. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
5. Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996;110:1515-9.
6. Steen VD. Systemic sclerosis and related syndrome: Clinical features. Primer on rheumatic diseases. In: Klippel JH, Crofford LJ, Stone JH, Weyand CM, editors. Atlanta: Atlanta Arthritis Foundation; 1997. p. 267-72.
7. Stupi AM, Steen VD, Owens GR, et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29:515-24.
8. Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 1990;21:467-74.
9. MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: Risk factors for progression and consequences for survival. Rheumatology 2001;40:453-9.
10. Ungerer RG, Tashkin DP, Furst D, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983;75:65-74.
11. Gugnani MK, Pierson C, Vanderheide R, et al. Pulmonary edema complicating prostacyclin therapy in pulmonary hypertension associated with scleroderma: A case of pulmonary capillary hemangiomatosis. Arthritis Rheum 2000;43:699-703
12. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991;34:978-83.
13. Atamas SP, Yurovsky VV, Wise R, et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999;42:1168-78.
14. Negi VS, Tripathy NK, Misra R, et al. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 1998;25:462-6.
15. Yoshio T, Masuyama J, Mimori A, et al. Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Ann Rheum Dis 1995;54:361-5.
16. Silver RM. Scleroderma. Clinical problems. The lungs. Rheum Dis Clin North Am 1996;22:825-40.
17. Cailes J, Winter S, du Bois RM, et al. Defective endothelially mediated pulmonary vasodilation in systemic sclerosis. Chest 1998;114:178-84.
18. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70-5.
19. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925-32.
20. Rubin LJ. Current concepts: Primary pulmonary hypertension. N Engl J Med 1997;336:111-7.
21. Yamane K, Ihn H, Asano Y, et al. Clinical and laboratory features of scleroderma patients with pulmonary hypertension. Rheumatology 2000;39:1269-71.
22. Steen VD, Graham G, Conte C, et al. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992;35:765-70.
23. Denton CP, Cailes JB, Phillips GD, et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997;36:239-43.
24. Menon N, McAlpine L, Peacock AJ, et al. The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis. Arthritis Rheum 1998;41:466-9.
25. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
26. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995;151:384-9.
27. White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000;132:947-54.
28. Akesson A. Cyclophosphamide therapy for scleroderma. Curr Opin Rheumatol 1998;10:579-83.
29. Pakas I, John PA. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheum 2002;29:298-304.
30. Matteson EL, Shbeeb MI, McCarthy TG, et al. Pilot study of antithymocyte globulin in systemic sclerosis. Arthritis Rheum 1996;39:1132-7.
31. Stratton RJ, Wilson H, Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology 2001;40:84-8.
32. Tarkowski A, Andersson-Gare B, Aurell M. Use of anti-thymocyte globulin in the management of refractory systemic autoimmune diseases. Scand J Rheumatol 1993;22:261-6.
33. Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001;44:1351-8.
34. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34.
35. Klings ES, Hill NS, Ieong MH, et al. Systemic sclerosis-associated pulmonary hypertension: Short- and long-term effects of epoprostenol (prostacyclin). Arthritis Rheum 1999;42:2638-45.
36. McLaughlin VV, Genthner DE, Panella MM, et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7.
37. Simonneau G, Barst RJ, Nazzareno G, et al. Continuous subcutaneous infusion of treprostenil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
38. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9.
39. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 2001;358:1119-23.
40. Bartosik I, Eskilsson J, Scheja A, et al. Intermittent iloprost infusion therapy of pulmonary hypertension in scleroderma - A pilot study. Br J Rheumatol 1996;35:1187-8.
41. Channick RN, Newhart JW, Johnson FW, et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: An ambulatory delivery system and initial clinical tests. Chest 1996;109:1545-9.
42. Cockrill BA, Kacmarek RM, Fifer MA, et al. Comparison of the effects of nitric oxide, nitroprusside, and nifedipine on hemodynamics and right ventricular contractility in patients with chronic pulmonary hypertension. Chest 2001;119:128-36.
43. Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999;34:1184-7.
44. Imai T, Saitoh K, Kani H, et al. Combined dose ratios of dopamine and dobutamine and right ventricular performance after cardiac surgery. Chest 1992;101:1197-202.
45. Poelaert JI, Mungroop HE, Koolen JJ, et al. Hemodynamic effects of dopexamine in patients following coronary artery bypass surgery. J Cardiothorac Anesth 1989;3:441-3.
46. Hess W. Effects of amrinone on the right side of the heart. J Cardiothorac Anesth 1989;3:38-44.
47. Solina A, Papp D, Ginsberg S, et al. A comparison of inhaled nitric oxide and milrinone for the treatment of pulmonary hypertension in adult cardiac surgery patients. J Cardiothorac Vasc Anesth 2000;14:12-7.
48. Eliasen K, Ringsted C, Munck O, et al. Pulmonary vasodilatation and augmentation of right ventricular function following terbutaline infusion in severe chronic pulmonary disease. Clin Physiol 1991;11:231-43.
49. Martin C, Perrin G, Saux P, et al. Effects of norepinephrine on right ventricular function in septic shock patients. Intensive Care Med 1994;20:444-7.
50. Vincent JL, Carlier E, Pinsky MR, et al. Prostaglandin E1 infusion for right ventricular failure after cardiac transplantation. J Thorac Cardiovasc Surg 1992;103:33-9.
51. Rich S, Gubin S, Hart K. The effects of phenylephrine on right ventricular performance in patients with pulmonary hypertension. Chest 1990;98:1102-6.
52. Rich S, Seidlitz M, Dodin E, et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998;114:787-92.
53. Allcock RJ, O'Sullivan JJ, Corris PA. Palliation of systemic sclerosis-associated pulmonary hypertension by atrial septostomy. Arthritis Rheum 2001;44:1660-2.
54. Newman ED, Harrington TM, Amoroso A. Endobronchial telangiectasias and hemoptysis in scleroderma. Am J Med 1988;84:173-4.
55. Helfrich DJ, Banner B, Steen VD, et al. Normatensive renal failure in systemic sclerosis. Arthritis Rheum 1989;32:1128-34.
56. Hara I, Miyake H. A case of progressive systemic sclerosis complicated by crescentic glomerulo-nephritis and diffuse pulmonary hemorrhage. Japanese Journal of Nephrology 1992;34:827-33.
57. Vazquez-Del Mercado M, Mendoza-Topete A, Best-Aguilera CR, et al. Diffuse alveolar hemorrhage in limited cutaneous systemic sclerosis with positive perinuclear antineutrophil cytoplasmic antibodies. J Rheumatol 1996;23:1821-3.
58. Endo H, Hosono T, Kondo H. Antineutrophil cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis. J Rheumatol 1994;21(5):864-70.
59. Nanke Y, Akama H, Yamanaka H, et al. Progressive appearance of overlap syndrome together with autoantibodies in a patient with fatal thrombotic microangiopathy. Am J Med Sci 2000;320:348-51.
60. Johnson DA, Drane WE, Curran J, et al. Pulmonary disease in progressive systemic sclerosis. A complication of gastroesophageal reflux and occult aspiration? Arch Intern Med 1989;149:589-93.
61. Steen VD, Medsger TAJ. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998;41:1613-9.
62. Kobayashi H, Nishimaki T, Kaise S, et al. Immunostological study endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis. Clin Rheumatol 1999;18:425-7.
63. Kfoury Baz EM, Mahfouz RA, Masri AF, et al. Thrombotic thrombocytopenic purpura in a case of scleroderma renal crisis treated with twice-daily therapeutic plasma exchange. Ren Fail 2001;23:737-42.
64. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am 1996;22:861-78.
65. Gunduz OH, Fertig N, Lucas M, et al. Systemic sclerosis with renal crisis and pulmonary hypertension: A report of eleven cases. Arthritis Rheum 2001;44:1663-6.
66. Gowda RM, Khan IA, Sacchi TJ, et al. Scleroderma pericardial disease presented with a large pericardial effusion - A case report. Angiology 2001;52:59-62.
67. Thompson AE, Pope JE. A study of the frequency of pericardial and pleural effusions in scleroderma. Br J Rheumatol 1998;37:1320-3.
68. Satoh M, Tokuhira M, Hama N, et al. Massive pericardial effusion in scleroderma: A review of five cases. Br J Rheumatol 1996;34:564-7.
69. Abu-Shakra M, Koh ET, Treger T, et al. Pericardial effusion and vasculitis in a patient with systemic sclerosis. J Rheumatol 1995;22:1386-8.
70. Sattar MA, Guindi R, Vajcik J. Pericardial tamponade and limited cutaneous systemic sclerosis (CREST syndrome). Br J Rheumatol 1990;29:306-7.
71. Uhl GS, Koppes GM. Pericardial tamponade in systemic sclerosis (scleroderma). Br Heart J 1979;42:345-8.
72. Perez-Bocanegra C, Fonollosa V, Simeon CP, et al. Pericardial tamponade preceding cutaneous involvement in systemic sclerosis. Ann Rheum Dis 1995;54:687-8.
73. Abu-Shakra M, Guillemin F, Lee P. Gastrointestinal manifestations of systemic sclerosis. Semin Arthritis Rheum 1994;24:29-39.
74. Folwaczny C, Voderholzer W, Riepl RL, et al. Clinical aspects, pathophysiology, diagnosis and therapy of gastrointestinal manifestations of progressive systemic scleroderma. Z Gastroenterol 1996;34:497-508.
75. Sjogren RW. Gastrointestinal features of scleroderma. Curr Opin Rheumatol 1996;8:569-75.